Form 4: Supernus CFO Sells Shares in Pre-Planned Transaction

Supernus Pharmaceuticals' Senior Vice-President and CFO, Timothy C. Dec, sold 11,780 shares of common stock for approximately $44.49 per share through a pre-arranged trading plan.

Summary

• Timothy C. Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 11,780 shares of common stock.
• The transaction occurred on August 22, 2025, at a weighted average price of $44.49 per share, with prices ranging from $44.40 to $44.66.
• This sale was conducted under a pre-arranged Rule 10b5-1(c) trading plan.
• Following the transaction, Mr. Dec beneficially owns 1,246 shares of Supernus common stock, which includes 345 shares acquired through the Issuer's Employee Stock Purchase Plan.
• The Form 4 was filed on August 26, 2025.

Sentiment

Score: 5

Explanation: The transaction is an insider sale, which can be viewed negatively, but it was pre-planned under a Rule 10b5-1 plan, mitigating immediate concerns about discretionary selling based on new information. Therefore, it is largely neutral.

Negatives

• The sale by a Senior Vice-President and CFO, Timothy C. Dec, of 11,780 shares represents a significant reduction in his direct holdings, which could be perceived as a lack of strong conviction by some investors.
• The total value of the shares sold is approximately $523,990.20.

Future Outlook

The filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May interpret the sale as a lack of confidence, though the pre-arranged 10b5-1 plan mitigates this concern by indicating a planned liquidity event rather than a reaction to new, undisclosed information.

Key Dates

Recommendation

The reported transaction is an insider sale by the CFO, but it was executed under a pre-arranged Rule 10b5-1 plan. Such plans are typically set up in advance to allow insiders to sell shares without being accused of trading on material non-public information. Therefore, this specific transaction is unlikely to reflect new negative sentiment about the company's immediate prospects and does not provide sufficient new information to alter a 'hold' recommendation.

Keywords

Supernus Pharmaceuticals, SUPN, insider trading, Form 4, stock sale, Timothy C. Dec, CFO, 10b5-1 plan